---
schema_version: "secwatch.filing_event.v1"
accession: "0001448431-25-000018"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:35:34.399068+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx posts Q3 net income of $0.8M, revenue up 22% to $26.1M; raises FY2025 outlook

## Summary
- Q3 revenue $26.1M (+22% YoY); GAAP net income $0.8M ($0.04/share) vs loss of $9.1M in Q3 2024.
- Adjusted EBITDA $5.1M (up from $2.7M); gross profit $17.5M (+30% YoY).
- Raised FY2025 guidance: revenue $105-109M, adjusted EBITDA $16-19M.
- Introduced FY2026 guidance: revenue $118-124M, adjusted EBITDA $19-22M.
- Cash $19.5M at Sep 30, 2025; paid $2M on term loan post-quarter.

## SEC filing metadata
- accession: 0001448431-25-000018
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000144843125000018/0001448431-25-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000144843125000018/oprx-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001448431-25-000018
- JSON: https://secwatch.observer/filing/0001448431-25-000018.json
- Plain text: https://secwatch.observer/filing/0001448431-25-000018.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.